| Abbreviation | Definition |
| AE | adverse event |
| AKI | acute kidney injury |
| ALT | alanine aminotransferase |
| AST | aspartate aminotransferase |
| BID | twice daily |
| BMI | body mass index |
| CI | confidence interval |
| DB | double blind |
| DBP | diastolic blood pressure |
| EFSA | European Food Safety Authority |
| FPG | fasting plasma glucose |
| GRADE | Grading of Recommendations Assessment, Development and Evaluation |
| HbA1c | glycated hemoglobin |
| HDL-C | high-density lipoprotein cholesterol |
| HOMA-IR | homeostatic model assessment of insulin resistance |
| LDL-C | low-density lipoprotein cholesterol |
| MIB-626 | microcrystalline β-nicotinamide mononucleotide formulation |
| NAD+ | nicotinamide adenine dinucleotide |
| NMN | nicotinamide mononucleotide |
| NR | not reported |
| OR | odds ratio |
| PC | Placebo controlled |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| QD | once daily |
| RCT | randomized controlled trial |
| RD | risk difference |
| RoB | risk of bias |
| SAE | serious adverse event |
| SBP | systolic blood pressure |
| SMD | standardized mean difference |
| T2DM | type 2 diabetes mellitus |
| TC | total cholesterol |
| TG | triglyceride |